经鼻高流量氧疗对慢性阻塞性肺疾病合并轻度高碳酸血症患者的影响:基于MIMIC-IV数据库的回顾性队列研究
本研究为基于MIMIC-IV数据库的回顾性队列研究,纳入2008至2019年成人COPD合并轻度高碳酸血症(45 mmHg < PaCO2 ≤ 60 mmHg)患者153例,HFNC组37例、NIV组116例,经倾向性评分匹配后HFNC组31例、NIV组84例。匹配后两组基线资料及预后指标除ICU住院时间外无显著差异,HFNC组ICU住院时间显著长于NIV组[4.6(3.1,10.0) vs. 3.1(1.6,5.8)天,P<0.05]。两组治疗后pH均升高、PaCO2均下降;HFNC组40-48小时HR和RR较0-8小时显著降低。HFNC组治疗后4小时HR/SpO2和ROX指数对24小时和48小时插管有预测价值,HR/SpO2的AUC大于ROX指数(24小时:0.649 vs. 0.574;48小时:0.692 vs. 0.581,均P<0.01),但ROX指数预测准确性差。结论认为HFNC可用于COPD合并轻度高碳酸血症患者,但不能替代NIV。
要点
- COPD合并轻度高碳酸血症(45 mmHg < PaCO2 ≤ 60 mmHg)患者中,HFNC组ICU住院时间显著长于NIV组[4.6(3.1,10.0) vs. 3.1(1.6,5.8)天,P<0.05]。
- 匹配后两组48小时和28天插管率、28天死亡率、住院时间等预后指标无显著差异,HFNC不能替代NIV。
- HFNC组治疗后40-48小时HR和RR较0-8小时显著降低[HR:84.1±12.2 vs. 91.1±16.4 bpm;RR:19.8±4.9 vs. 21.6±4.1次/分,均P<0.05];NIV组无此变化。
- HFNC组治疗后4小时HR/SpO2预测24小时和48小时插管的AUC分别为0.649和0.692,均大于ROX指数(0.574和0.581,均P<0.01),但ROX指数预测准确性差。
- HFNC组4小时HR/SpO2预测24小时和48小时插管的敏感度分别为84.6%和92.9%,特异度分别为52.3%和54.7%;ROX指数敏感度88.2%和94.4%,特异度23.7%和29.6%。
适用人群与场景
- 基于MIMIC-IV数据库2008至2019年成人COPD合并轻度高碳酸血症患者,纳入标准为45 mmHg < PaCO2 ≤ 60 mmHg。
- 根据是否接受HFNC或NIV分为HFNC组和NIV组,经倾向性评分匹配后HFNC组31例、NIV组84例。
- 原文未提及排除人群及具体急诊/ICU/院前场景。
诊断标准与关键阈值
- 轻度高碳酸血症定义:45 mmHg(1 mmHg=0.133 kPa)< 动脉血二氧化碳分压(PaCO2)≤ 60 mmHg。
- 原文未提及HFNC启动、停止或升级至插管的具体阈值。
处置流程与药物剂量
- 原文未提及HFNC具体流量、FiO2、温度及NIV具体参数设置。
- 原文未提及药物剂量、给药途径、频次或疗程。
- 原文未提及HFNC或NIV的治疗目标值(如SpO2目标范围)。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征及相应处理。
研究设计与关键结果
- 研究类型:基于MIMIC-IV数据库的回顾性队列研究;筛选524 520份住院记录,纳入153例(HFNC组37例、NIV组116例),倾向性评分匹配后HFNC组31例、NIV组84例。
- 匹配后两组基线资料(性别、年龄、BMI、SAPS II、CCI评分、生理参数)及预后数据除ICU住院时间外无显著差异。
- HFNC组ICU住院时间显著长于NIV组[4.6(3.1,10.0) vs. 3.1(1.6,5.8)天,P<0.05]。
- 两组治疗后pH均升高(HFNC组7.42±0.08 vs. 7.36±0.05;NIV组7.41±0.06 vs. 7.36±0.05,均P<0.05),PaCO2均下降[HFNC组46.3(39.5,51.0) vs. 49.8(45.5,54.0) mmHg;NIV组46.0(40.5,51.5) vs. 49.5(45.5,55.3) mmHg,均P<0.05]。
- HFNC组40-48小时HR和RR较0-8小时显著降低[HR:84.1±12.2 vs. 91.1±16.4 bpm;RR:19.8±4.9 vs. 21.6±4.1次/分,均P<0.05],NIV组无此变化。
- HFNC组治疗后4小时HR/SpO2和ROX指数对24小时和48小时插管有预测价值;HR/SpO2的AUC大于ROX指数(24小时:0.649 vs. 0.574;48小时:0.692 vs. 0.581,均P<0.01),95%CI分别为0.497-0.780、0.567-0.799、0.450-0.694、0.454-0.716。
- HFNC组4小时HR/SpO2预测24小时和48小时插管的敏感度为84.6%、92.9%,特异度为52.3%、54.7%;ROX指数敏感度为88.2%、94.4%,特异度为23.7%、29.6%。
证据类型、等级与局限
- 证据类型:基于MIMIC-IV数据库的回顾性队列研究。
- 局限:回顾性研究、样本量小(匹配后HFNC组31例、NIV组84例)、单数据库来源;原文未提及开放标签或单中心等信息。
对床旁实践的改变
- COPD合并轻度高碳酸血症(45 mmHg < PaCO2 ≤ 60 mmHg)患者可考虑使用HFNC,但不应以HFNC替代NIV。
- 使用HFNC期间应关注ICU住院时间可能延长(HFNC组4.6天 vs. NIV组3.1天,P<0.05)。
- HFNC治疗后4小时ROX指数预测插管准确性差,不宜单独依据ROX指数决定是否插管;HR/SpO2的AUC虽大于ROX指数但绝对值仍较低(0.649和0.692),原文未推荐将其作为决策阈值。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To observe the effect of high-flow nasal cannula oxygen therapy (HFNC) in patients with chronic obstructive pulmonary disease (COPD) and mild hypercapnia, and to evaluate the early predictive ability of physiological parameters in these patients.
METHODS: A retrospective cohort study was conducted based on Medical Information Mart for Intensive Care-IV (MIMIC-IV) updated in September 2020 and the data of adult patients with COPD and mild hypercapnia [45 mmHg (1 mmHg = 0.133 kPa) < arterial partial pressure of carbon dioxide (PaCO2) ≤ 60 mmHg] from 2008 to 2019 were collected. These patients were assigned to the HFNC group or non-invasive ventilation (NIV) group according to whether they received HFNC or NIV. Baseline data such as gender, age, body mass index (BMI), simplified acute physiology score II (SAPS II), Charlson comorbidity index (CCI) and physiological parameters were collected. A propensity score matching was conducted according to the baseline data of the HFNC group patients. The 48-hour and 28-day intubation rates, 28-day mortality, length of intensive care unit (ICU) stay, the length of hospital stay, and the changes in physiological parameters within 48 hours after treatment were compared between the two groups. The receiver operating characteristic curve (ROC curve) was drawn and the ratio of heart rate over pulse oxygen saturation (HR/SpO2) and ROX index [SpO2/(inhaled oxygen concentration, FiO2×respiratory rate, RR)] were analyzed to predict the 24-hour and 48-hour intubation rates.
RESULTS: A total of 524 520 inpatient records were screened and 153 patients were included, while 37 patients in the HFNC group and 116 patients in NIV group. There were 31 patients in the HFNC group and 84 patients in the NIV group remained after propensity score matching according to the baseline data. There were no significant differences in the baseline data of gender, age, BMI, SAPS II, CCI score, physiological parameters and prognosis data except the length of ICU stay. The length of ICU stay in HFNC group was significant longer than that of the NIV group [days: 4.6 (3.1, 10.0) vs. 3.1 (1.6, 5.8), P < 0.05]. HR and RR at 40-48 hours were significantly lower than those at 0-8 hours after treatment only in the HFNC group [HR (bpm): 84.1±12.2 vs. 91.1±16.4, RR (times/min): 19.8±4.9 vs. 21.6±4.1, both P < 0.05]. Both in the HFNC group and NIV group the pH increased (7.42±0.08 vs. 7.36±0.05 and 7.41±0.06 vs. 7.36±0.05, both P < 0.05) and PaCO2 decreased significantly [mmHg: 46.3 (39.5, 51.0) vs. 49.8 (45.5, 54.0) and 46.0 (40.5, 51.5) vs. 49.5 (45.5, 55.3), both P < 0.05]. The HR, PaO2 were higher in the HFNC group than those in the HFNC group at 40-48 hours after treatment [HR (bpm): 91.1±15.4 vs. 84.1±12.2, PaO2 (mmHg): 99.5 (86.0, 132.3) vs. 85.8 (76.5, 118.0), both P < 0.05], PaO2/FiO2 were lower in the HFNC group than that in the HFNC group at 40-48 hours after treatment [mmHg: 223.8 (216.5, 285.0) vs. 278.0 (212.3, 306.0), P < 0.05]. Both HR/SpO2 and ROX index at 4 hours after treatment had predictive value for 24-hour and 48-hour intubation in the HFNC group. The areas under ROC curve (AUC) of HR/SpO2 at 4 hours after treatment in the HFNC group were larger than those of ROX index for predicting 24-hour and 48-hour intubation (24-hour: 0.649 vs. 0.574, 48-hour: 0.692 vs. 0.581, both P < 0.01); the 95% confidence interval (95%CI) of 4 hours HR/SpO2 and for ROX index predicting 24 hours and 48 hours intubation were 0.497-0.780, 0.567-0.799, 0.450-0.694 and 0.454-0.716, respectively. The high sensitivity of HR/SpO2 and ROX index in predicting 24-hour and 48-hour intubation were 84.6%, 92.9%, 88.2% and 94.4%, respectively, and the low specificity were 52.3%, 23.7%, 54.7% and 29.6%, respectively.
CONCLUSIONS: HFNC can be used in COPD patients with mild hypercapnia, but it cannot replace NIV. The accuracy of ROX index at 4 hours after HFNC treatment in predicting intubation in COPD patients with mild hypercapnia is poor.
参考来源
- Liu T, Zhao Q, Shi Z, et al. [Effect of high-flow nasal cannula oxygen on patients with chronic obstructive pulmonary disease and mild hypercapnia: a retrospective cohort study based on the Medical Information Mart for Intensive Care-IV database]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34296687. doi:10.3760/cma.j.cn121430-20210219-00258
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。